Hours
Minutes
Seconds

ICH E6(R3): Good Clinical Practice Changes and Key Dates

Illustration of a GCP guideline binder with checklists, a magnifying glass over a trial document and a quality shield for ICH E6(R3)

Definition

ICH E6(R3) is the third revision of the ICH Guideline for Good Clinical Practice (GCP). It replaces E6(R2) with 11 overarching principles, Annex 1 for interventional clinical trials and Annex 2 for trials with decentralized, pragmatic or real-world data elements. ICH adopted the principles and Annex 1 on January 6, 2025, and Annex 2 on June 3, 2026.

  • EU: principles and Annex 1 apply since July 23, 2025; Annex 2 applies from January 15, 2027.
  • US: FDA issued E6(R3) as final guidance in September 2025. Its Annex 2 page still shows the December 2024 draft.
  • Core shift: quality by design, critical to quality factors, risk-proportionate processes and “essential records” instead of “essential documents”.

Updated November 19, 2026

Where you learn this: the E6(R3) principles, Annex 1 and the appendices are covered step by step, with knowledge checks, in the VIARES course Navigating ICH GCP E6(R3).

Key dates at a glance

Dates from the ICH document history, the EMA guideline page and the FDA guidance pages (see Sources). Status checked November 19, 2026.
Milestone Date
ICH E6(R3) draft released for public consultation (Step 2) May 19, 2023
ICH adopts the principles and Annex 1 (Step 4) January 6, 2025
Principles and Annex 1 take effect in the EU (EMA) July 23, 2025
FDA publishes E6(R3) as final guidance for industry September 2025
ICH adopts Annex 2 (Step 4) June 3, 2026
ICH publishes the consolidated guideline (principles, Annex 1 and Annex 2) June 16, 2026
Annex 2 takes effect in the EU (EMA) January 15, 2027

What is ICH E6(R3)?

ICH, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, publishes E6 as the international standard for Good Clinical Practice. GCP helps assure that the rights, safety and well-being of trial participants are protected and that clinical trial results are reliable. In the guideline, “trial conduct” runs from planning to reporting of clinical trials. Its objective is the mutual acceptance of clinical trial data by regulatory authorities in ICH member countries and regions.

E6(R3) applies to interventional clinical trials of investigational products intended for submission to regulatory authorities. It is written to be media neutral, so the same rules work for paper, electronic systems and digital health technologies such as wearables. The use of technology should fit the participants and the clinical trial design. The new guideline has a modular structure:

  • ✓ Principles of ICH GCP: 11 interdependent principles that apply across trial types and settings.
  • ✓ Annex 1: how the principles apply to interventional trials, in four sections: IRB/IEC, investigator, sponsor and data governance.
  • ✓ Appendices to Annex 1: A. Investigator’s Brochure, B. clinical trial protocol and amendments, C. essential records. A glossary closes the document.
  • ✓ Annex 2: additional GCP considerations for trials with decentralized elements, pragmatic elements and real-world data sources. It is read together with the principles and Annex 1.

Why E6(R2) was revised

The first ICH E6 guideline reached Step 4 on May 1, 1996. E6(R2), adopted on November 9, 2016, was an integrated addendum to that text. It added risk-based quality management for sponsors and gave more room for centralized monitoring.

Trial designs, data sources and technology kept changing. E6(R3) builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies: a quality culture, designing quality into clinical trials and drug development planning, identifying factors critical to trial quality and a proportionate, risk-based approach. EMA describes the new structure as a package that serves as a replacement for ICH E6(R2).

E6(R2) vs E6(R3)

Comparison based on the official ICH E6(R2) and E6(R3) texts.
Topic ICH GCP E6(R2) ICH GCP E6(R3)
Structure One document in 8 sections, starting with the glossary Principles, Annex 1 with Appendices A to C, Annex 2, glossary at the end
Principles 13 principles 11 principles, each with detailed sub-points
Quality Risk-based quality management added for the sponsor in 2016 Quality by design and critical to quality factors are part of the principles; processes proportionate to risk
Records “Essential documents” listed in section 8 “Essential records” in Appendix C; which records are essential depends on trial design and risk
Data Data handling spread across sections Dedicated data governance section for investigator and sponsor; computerized systems fit for purpose
Delegation Sponsor may transfer duties to a CRO; investigator supervises delegated persons and parties Sponsor and investigator may transfer or delegate activities, including to service providers, but keep overall responsibility and oversight
Technology Electronic data systems covered mainly in sponsor data handling (5.5.3) Media neutral; remote consent, remote site monitoring and decentralized elements addressed
Wording “Trial subjects” “Trial participants”

The risk-based approach is not new in R3. What is new is that it moves from sponsor quality management into the principles, so it shapes the whole trial life cycle, from trial design to reporting.

When E6(R3) takes effect

Step 4 means ICH regulatory members endorsed the final text; each regulator then implements it (Step 5).

  • ✓ European Union: EMA states that the principles and Annex 1 came into effect on July 23, 2025. Annex 2 was adopted by CHMP on June 25, 2026 and comes into effect on January 15, 2027.
  • ✓ United States: FDA published “E6(R3) Good Clinical Practice” as final guidance for industry in September 2025. FDA guidance describes the agency’s current thinking and is not legally binding unless specific regulations or statutes are cited. FDA’s Annex 2 page still lists the December 2024 draft, marked “not for implementation”.
  • ✓ Other ICH regions: check the national regulator for its own implementation date.

The 11 GCP principles

  1. Ethics: trials follow the Declaration of Helsinki; participants’ rights, safety and well-being come first.
  2. Informed consent is voluntary and based on a process that keeps participants well informed.
  3. Independent review by institutional review boards or independent ethics committees, IRB/IEC (see research ethics board).
  4. Trials are scientifically sound for their intended purpose.
  5. Trials are designed and conducted by qualified individuals.
  6. Quality is built into the scientific and operational design and conduct.
  7. Processes are proportionate to the risks to participants and the importance of the data collected, without unnecessary data collection.
  8. The protocol is clear, concise, scientifically sound and operationally feasible.
  9. Trials generate reliable results.
  10. Roles and responsibilities are clear and documented.
  11. Investigational products are manufactured under GMP and managed according to product specifications and the protocol.

ICH notes that the principles are interdependent and should be considered in their totality to assure ethical trial conduct and reliable results. They are meant to support efficient approaches to trial design and conduct. Principle 6 defines quality as “fitness for purpose”. Critical to quality factors are the attributes of a trial that matter most for participant protection and for reliable, interpretable results. They are identified prospectively.

What changes for your role

  • ✓ Sponsor: sets the extent and nature of monitoring based on identified risks, keeps oversight of service providers and makes sure computerized systems are fit for purpose.
  • ✓ Investigator: keeps overall responsibility for activities delegated to site staff or service providers and controls the essential records generated at the site. See clinical investigator.
  • ✓ CRA and monitors: monitoring can combine on-site and remote site visits with centralized monitoring. Annex 1 says centralized monitoring can complement and reduce site monitoring or be used on its own (see remote and centralized monitoring).
  • ✓ Data management: data governance covers the full data life cycle, from data collection to archiving, so data integrity and traceability are planned, not checked only at the end.

Example: a monitoring plan

Illustrative scenario, not a real trial. A sponsor plans a multicenter trial with a blood pressure endpoint. At the design stage, the team names its critical to quality factors: correct eligibility, the primary endpoint measurement, safety reporting and informed consent.

  • ✓ Risk-based monitoring plan: source data verification focuses on eligibility and endpoint data. Centralized data analytics flag sites with unusual values or late data entry.
  • ✓ Visit frequency: the CRA visits a site more often when indicators rise and less often when data look clean, as Annex 1 allows.
  • ✓ Service provider oversight: the central lab and the eCOA vendor have written agreements; the sponsor reviews their performance, because responsibility stays with the sponsor.
  • ✓ Essential records: the TMF specialist files records by their essentiality for the trial, not from a one-size-fits-all checklist.

Monitoring effort goes where errors would hurt participants or the results most; routine quality control continues in proportion to risk.

Where you learn this at VIARES

If your existing GCP training is based on E6(R2), the Navigating ICH GCP E6(R3) course guides you through the transition from E6(R2) to E6(R3) in microcourses:

  • ✓ E6(R3) Principles: GCP definition and purpose, the structure and emphasis of E6(R2) vs E6(R3), the purpose of the revision and the amended principles.
  • ✓ Annex I: IRB/IEC and its composition, investigator, sponsor and data governance, including decentralized clinical trials.
  • ✓ Appendices: the Investigator’s Brochure, protocol and amendments (including estimands and Bayesian design) and essential records.
  • ✓ Knowledge checks and exam: each module ends with a knowledge check (pass mark 70%), followed by a certification exam and a VIARES certificate that can be verified online by code.

If you are training for a monitoring career, the Clinical Research Associate course covers the principles of GCP and how they protect patient safety and data integrity. Looking for a GCP certificate instead? See GCP certification.

FAQ

What is the ICH E6 R3 guideline?

ICH E6(R3) is the current ICH Guideline for Good Clinical Practice, the international ethical, scientific and quality standard for clinical trials with human participants. It consists of 11 principles, Annex 1 for interventional trials with appendices on the Investigator’s Brochure, protocol and essential records, and Annex 2 for decentralized, pragmatic and real-world data elements.

What is the difference between ICH E6 R2 and R3?

E6(R3) has a new modular structure (principles plus annexes) and 11 instead of 13 principles. It puts quality by design, critical to quality factors and risk-proportionate processes into the principles, replaces “essential documents” with “essential records”, adds a data governance section and is media neutral, so it fits electronic systems, remote processes and decentralized elements.

Is ICH E6 R3 effective in the US?

FDA published E6(R3) Good Clinical Practice as final guidance for industry in September 2025. Like all FDA guidance, it gives nonbinding recommendations that reflect the agency’s current thinking, while FDA regulations stay binding. Annex 2 is still shown as a December 2024 draft on FDA’s guidance page.

When does ICH E6 R3 go into effect?

ICH adopted the principles and Annex 1 on January 6, 2025, and Annex 2 on June 3, 2026. In the EU, the principles and Annex 1 have applied since July 23, 2025, and Annex 2 applies from January 15, 2027. Other regulators set their own implementation dates.

Sources

  1. ICH E6(R3) Guideline for Good Clinical Practice, Step 4 final version adopted January 6, 2025: document history, Introduction, Guideline Structure, Principles 1 to 11, Annex 1 sections 2 to 4, 3.11.4, Appendix C
  2. ICH E6(R3) consolidated guideline (principles, Annex 1 and Annex 2), adopted June 16, 2026: document history including Annex 2 Step 4 on June 3, 2026
  3. ICH E6(R2) Integrated Addendum to ICH E6(R1), Step 4 November 9, 2016: sections 2, 5.0, 5.2.1, 5.18.3 and 8
  4. European Medicines Agency. ICH E6 Good clinical practice, scientific guideline (effective dates for principles, Annex 1 and Annex 2)
  5. European Medicines Agency. ICH E6(R3) Annex 2, Step 5 (date for coming into effect: January 15, 2027)
  6. U.S. Food and Drug Administration. E6(R3) Good Clinical Practice (GCP), final guidance, September 2025
  7. U.S. Food and Drug Administration. E6(R3) Good Clinical Practice, Guidance for Industry (PDF), September 2025: “Contains Nonbinding Recommendations”
  8. U.S. Food and Drug Administration. E6(R3) Good Clinical Practice: Annex 2, draft guidance, December 2024


Never Miss an important topic

Subscribe to our newsletter and recieve up-to-date information directly into your inbox:

Get a free micro certificate
ICH E6(R3): Good Clinical Practice Changes and Key Dates

Enroll now for free and take a short quiz

elevate your skill level

Other Blog-Posts

Clinical Research certification courses & Packages

Clinical Research Online Courses VIARES
BEST VALUE
ALL courses for the price of 2! Transform your clinical research career with our comprehensive training bundle! By enrolling in all courses, you’ll gain expertise across trial documentation, monitoring trials, project and site management, regulatory compliance, oncology research, remote monitoring and all you need for your clinical research career.
clinical research online course - CRA clinical research associate
TOP COURSE
Step into the role of a Clinical Research Associate! This course covers clinical trial management, regulatory compliance, and data quality. Master the skills to monitor trial sites, ensure patient safety, and support groundbreaking research—your career in clinical research starts here.
Woman using laptop with text Navigating ICH GCP E6(R3).
HOT NOW
Navigate ICH-GCP E6(R3) standards with confidence! This course provides comprehensive training on ethical guidelines, regulatory compliance, and trial management. Gain the expertise needed to ensure high standards in clinical trials worldwide—start enhancing your clinical research knowledge today!